Journal of Community Hospital Internal Medicine Perspectives

Volume 13 | Issue 1 Article 17

# Recurrence of Thrombotic Thrombocytopenic Purpura After COVID-19 Vaccination: correspondence

Mungmunpuntipantip Rujittika
*Private Academic Consultant, Bangkok Thailand*, rujittika@gmail.com

Viroj Wiwanitkit
*Chandigarh University, Punjab, India*



## Recommended Citation

Rujittika, Mungmunpuntipantip and Wiwanitkit, Viroj () "Recurrence of Thrombotic Thrombocytopenic Purpura After COVID-19 Vaccination: correspondence," *Journal of Community Hospital Internal Medicine Perspectives*: Vol. 13: Iss. 1, Article 17.
DOI: 10.55729/2000-9666.1154
Available at: https://scholarlycommons.gbmc.org/jchimp/vol13/iss1/17

# Recurrence of Thrombotic Thrombocytopenic Purpura After COVID-19 Vaccination: Correspondence

Rujittika Mungmunpuntipantip [a,*], Viroj Wiwanitkit [b]

[a] Bangkok, Thailand
[b] Chandigarh University, Punjab, India

*Dear Editor,*

We would like to share ideas on "Recurrence of Thrombotic Thrombocytopenic Purpura After Vaccination with mRNA-1273 COVID-19 vaccine.[1]" Ntelis and Champ describe a 63-year-old woman who, 33 days after receiving the second dose of the mRNA-1273 COVID-19 vaccine, began experiencing chest tightness, low-grade fever, and bruising. She had previously been diagnosed with hypertension, diabetes mellitus, chronic kidney disease, HIV infection, and distant history of TTP. Following COVID-19 immunization, Ntelis and Champ came to the conclusion that TTP should be taken into account in patients who come with thrombocytopenia,[1] particularly if there is a history of TTP.

The vaccine is beneficial, but there is a potential that it could also be harmful. This scenario could be used as a good example. But it's crucial to take into account the alternatives. The vaccine is beneficial, but there is a potential that it could also be harmful. This scenario could be used as a good example. But it's crucial to take into account the alternatives. It's critical to eliminate any concurrent comorbid conditions when a post-vaccination adverse effect is detected.[2] Sometimes comorbidity, such as dengue, can have clinical problems and be misconstrued.[2]

## Conflict of interest

None.

## References

1. Ntelis S, Champ K. Recurrence of thrombotic thrombocytopenic Purpura after vaccination with mRNA-1273 COVID-19 vaccine. *J Community Hosp Intern Med Perspect*. 2022 Jul 4;12(4): 80–84.
2. Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. *Clin Appl Thromb Hemost*. 2021 Jan-Dec;27: 10760296211047229.

Received 21 October 2022; revised 18 November 2022; accepted 21 November 2022.
Available online 10 January 2023

* Corresponding author at:
E-mail address: rujittika@gmail.com (R. Mungmunpuntipantip).

https://doi.org/10.55729/2000-9666.1154